Compare Stocks: RNA, FTH, PHAR, and ACRS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.92 +2.4%	$5.30	$1.74 ▼ $6.51	$808.18M	0.78	1.84 million shs	1.09 million shs
FTH Sensei Biotherapeutics	$32.77 +1.3%	$26.79	$7.21 ▼ $37.90	$835.68M	-0.25	289,796 shs	416,841 shs
PHAR Pharming Group	$11.79 +0.6%	$12.66	$9.62 ▼ $21.34	$829.52M	-0.01	20,842 shs	17,279 shs
RNA Avidity Biosciences	$12.96 +0.9%	$12.40	$11.13 ▼ $16.77	$219.64M	N/A	123,500 shs	212,552 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+2.42%	+0.34%	+4.23%	+33.03%	+216.58%
FTH Sensei Biotherapeutics	+1.33%	+14.70%	+26.67%	+3,276,999,900.00%	+3,276,999,900.00%
PHAR Pharming Group	+0.60%	+3.88%	-12.47%	-6.58%	+1.20%
RNA Avidity Biosciences	+0.93%	+5.88%	+6.67%	+0.08%	-72.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$5.92 +2.4%	$5.30	$1.74 ▼ $6.51	$808.18M	0.78	1.84 million shs	1.09 million shs
FTH Sensei Biotherapeutics	$32.77 +1.3%	$26.79	$7.21 ▼ $37.90	$835.68M	-0.25	289,796 shs	416,841 shs
PHAR Pharming Group	$11.79 +0.6%	$12.66	$9.62 ▼ $21.34	$829.52M	-0.01	20,842 shs	17,279 shs
RNA Avidity Biosciences	$12.96 +0.9%	$12.40	$11.13 ▼ $16.77	$219.64M	N/A	123,500 shs	212,552 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+2.42%	+0.34%	+4.23%	+33.03%	+216.58%
FTH Sensei Biotherapeutics	+1.33%	+14.70%	+26.67%	+3,276,999,900.00%	+3,276,999,900.00%
PHAR Pharming Group	+0.60%	+3.88%	-12.47%	-6.58%	+1.20%
RNA Avidity Biosciences	+0.93%	+5.88%	+6.67%	+0.08%	-72.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	94.26% Upside
FTH Sensei Biotherapeutics	2.83	Moderate Buy	$54.90	67.53% Upside
PHAR Pharming Group	2.20	Hold	$38.67	227.96% Upside
RNA Avidity Biosciences	2.29	Hold	$63.85	392.64% Upside

Current Analyst Ratings Breakdown

Latest RNA, FTH, PHAR, and ACRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/7/2026	PHAR Pharming Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
8/3/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/31/2026	PHAR Pharming Group	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/30/2026	PHAR Pharming Group	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	105.71	N/A	N/A	$0.85 per share	6.96
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
PHAR Pharming Group	$376.13M	2.22	$0.20 per share	58.44	$3.95 per share	2.98
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
PHAR Pharming Group	$2.85M	$0.12	98.25	39.30	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$0.97	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RNA, FTH, PHAR, and ACRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
FTH Sensei Biotherapeutics	N/A	19.69	19.69
PHAR Pharming Group	0.34	3.01	2.31
RNA Avidity Biosciences	N/A	8.73	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
FTH Sensei Biotherapeutics	10.50%
PHAR Pharming Group	0.03%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
FTH Sensei Biotherapeutics	7.00%
PHAR Pharming Group	2.07%
RNA Avidity Biosciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable
PHAR Pharming Group	280	70.78 million	69.31 million	Not Optionable
RNA Avidity Biosciences	190	17.11 million	N/A	Optionable

RNA, FTH, PHAR, and ACRS Headlines

Recent News About These Companies

Avidity Biosciences' (RNA) "Buy" Rating Reiterated at HC Wainwright

August 17 at 2:01 AM | americanbankingnews.com

Avidity Biosciences' (RNA) Buy Rating Reaffirmed at HC Wainwright

August 14, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results

August 13, 2026 | marketbeat.com

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

August 13, 2026 | prnewswire.com

Q3 Earnings Estimate for RNA Issued By HC Wainwright

August 10, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Research Coverage Started at HC Wainwright

August 9, 2026 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Now Covered by HC Wainwright

August 6, 2026 | marketbeat.com

Avidity Biosciences (RNA) Expected to Announce Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Analysts

July 31, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average - Here's Why

July 22, 2026 | marketbeat.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | prnewswire.com

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

July 14, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026 | prnewswire.com

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

June 14, 2026 | finance.yahoo.com

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

June 12, 2026 | biopharmadive.comB

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

April 23, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 20, 2026 | prnewswire.com

Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline

March 19, 2026 | uk.finance.yahoo.com

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

March 19, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNA, FTH, PHAR, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$5.92 +0.14 (+2.42%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$5.86 -0.06 (-1.05%)

As of 07:02 AM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Sensei Biotherapeutics NASDAQ:FTH

$32.77 +0.43 (+1.33%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$32.16 -0.61 (-1.87%)

As of 07:00 AM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Pharming Group NASDAQ:PHAR

$11.79 +0.07 (+0.60%)

Closing price 08/17/2026 03:58 PM Eastern

Extended Trading

$11.80 +0.01 (+0.08%)

As of 04:08 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Avidity Biosciences NASDAQ:RNA

$12.96 +0.12 (+0.93%)

As of 08/17/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNA, FTH, PHAR, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNA, FTH, PHAR, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNA, FTH, PHAR, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNA, FTH, PHAR, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Sensei Biotherapeutics NASDAQ:FTH

Pharming Group NASDAQ:PHAR

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNA, FTH, PHAR, and ACRS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNA, FTH, PHAR, and ACRS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNA, FTH, PHAR, and ACRS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNA, FTH, PHAR, and ACRS Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

Sensei Biotherapeutics NASDAQ:FTH

Pharming Group NASDAQ:PHAR

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools